Ironwood Pharmaceuticals (NASDAQ: IRWD) insider transactions
In the twelve months to 10 November 2026, executives and directors of Ironwood Pharmaceuticals reported 18 open-market sales of 7,256,693 shares ($22.6m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 15 September 2026 | Denner Alexander J | Director | Grant or award | +3,694 | — | 327,549 | Form 4 |
| 20 July 2026 | Silber Jeffrey | SVP, CMO, Head-Res&Drug | Grant or award | +137,036 | — | 137,036 | Form 4 |
| 7 July 2026 | Silver Ronald | Pfo & Pao | Open-market sale | −127,890 | $4.52 | 313,680 | Form 4 |
| 16 June 2026 | Moukheibir Catherine | Director | Grant or award | +63,481 | — | 181,425 | Form 4 |
| 16 June 2026 | McHugh Julie | Director | Grant or award | +63,481 | — | 272,320 | Form 4 |
| 16 June 2026 | McHugh Julie | Director | Open-market sale | −21,571 | $3.73 | 250,749 | Form 4 |
| 16 June 2026 | Denner Alexander J | Director | Grant or award | +63,481 | — | 323,855 | Form 4 |
| 16 June 2026 | Duane Jon R | Director | Grant or award | +63,481 | — | 253,820 | Form 4 |
| 16 June 2026 | Currie Mark G | Director | Grant or award | +63,481 | — | 676,900 | Form 4 |
| 16 June 2026 | Kessler Marla L | Director | Grant or award | +63,481 | — | 229,364 | Form 4 |
| 16 June 2026 | Shepard Jay | Director | Grant or award | +63,481 | — | 235,036 | Form 4 |
| 15 June 2026 | Denner Alexander J | Director | Grant or award | +4,065 | — | 260,374 | Form 4 |
| 19 May 2026 | Silver Ronald | Pfo & Pao | Grant or award | +25,000 | — | 441,570 | Form 4 |
| 17 March 2026 | Denner Alexander J | Director | Open-market sale | −6,725,000 | $3.05 | 9,194,435 | Form 4 |
| 17 March 2026 | Denner Alexander J | Director | Open-market sale | −5,800 | $3.31 | 9,188,635 | Form 4 |
| 13 March 2026 | Denner Alexander J | Director | Grant or award | +4,451 | — | 256,309 | Form 4 |
| 10 March 2026 | MCCOURT Thomas A | Chief Executive Officer | Grant or award | +409,836 | — | 1,898,838 | Form 4 |
| 10 March 2026 | Martini Gregory S. | Chief Financial Officer | Grant or award | +136,612 | — | 297,213 | Form 4 |
| 10 March 2026 | John Minardo | Chief Legal Officer | Grant or award | +136,612 | — | 500,498 | Form 4 |
| 10 March 2026 | Silver Ronald | Principal Accounting Officer | Grant or award | +163,934 | — | 416,570 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Ironwood Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.